Centessa Pharmaceuticals Initiates Phase 1 Clinical Trial of ORX142 for Sleep-Deprived Volunteers, Expects Key Data in 2025

Reuters

08/12

Centessa Pharmaceuticals Initiates Phase 1 Clinical Trial of ORX142 for Sleep-Deprived Volunteers, Expects Key Data in 2025

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, has announced significant progress in its orexin receptor 2 (OX2R) agonist pipeline. The company reported that its ORX750 Phase 2a CRYSTAL-1 study, targeting narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia $(IH)$, is on track with data expected to be released later this year. Additionally, Centessa has initiated a Phase 1 clinical trial of ORX142, focusing on acutely sleep-deprived healthy volunteers, with results anticipated in 2025. Furthermore, ORX489 is currently in IND-enabling studies for the treatment of neuropsychiatric disorders. An abstract detailing the ORX750 study has been accepted for a poster presentation at the World Sleep 2025 Congress, and a copy will be available on the Centessa website concurrent with the presentation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9510438-en) on August 12, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2558649104"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2558649104\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2558649104?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-12 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558649104","market":"fut","top_or_hot":-1,"title":"Centessa Pharmaceuticals Initiates Phase 1 Clinical Trial of ORX142 for Sleep-Deprived Volunteers, Expects Key Data in 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Centessa Pharmaceuticals Initiates Phase 1 Clinical Trial of ORX142 for Sleep-Deprived Volunteers, Expects Key Data in 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CNTA\">Centessa Pharmaceuticals plc</a>, a clinical-stage pharmaceutical company, has announced significant progress in its orexin receptor 2 (OX2R) agonist pipeline. The company reported that its ORX750 Phase 2a CRYSTAL-1 study, targeting narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia <a href=\"https://laohu8.com/S/IH\">$(IH)$</a>, is on track with data expected to be released later this year. Additionally, Centessa has initiated a Phase 1 clinical trial of ORX142, focusing on acutely sleep-deprived healthy volunteers, with results anticipated in 2025. Furthermore, ORX489 is currently in IND-enabling studies for the treatment of neuropsychiatric disorders. An abstract detailing the ORX750 study has been accepted for a poster presentation at the World Sleep 2025 Congress, and a copy will be available on the Centessa website concurrent with the presentation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9510438-en) on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Centessa Pharmaceuticals Initiates Phase 1 Clinical Trial of ORX142 for Sleep-Deprived Volunteers, Expects Key Data in 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCentessa Pharmaceuticals Initiates Phase 1 Clinical Trial of ORX142 for Sleep-Deprived Volunteers, Expects Key Data in 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-12 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Centessa Pharmaceuticals Initiates Phase 1 Clinical Trial of ORX142 for Sleep-Deprived Volunteers, Expects Key Data in 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CNTA\">Centessa Pharmaceuticals plc</a>, a clinical-stage pharmaceutical company, has announced significant progress in its orexin receptor 2 (OX2R) agonist pipeline. The company reported that its ORX750 Phase 2a CRYSTAL-1 study, targeting narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia <a href=\"https://laohu8.com/S/IH\">$(IH)$</a>, is on track with data expected to be released later this year. Additionally, Centessa has initiated a Phase 1 clinical trial of ORX142, focusing on acutely sleep-deprived healthy volunteers, with results anticipated in 2025. Furthermore, ORX489 is currently in IND-enabling studies for the treatment of neuropsychiatric disorders. An abstract detailing the ORX750 study has been accepted for a poster presentation at the World Sleep 2025 Congress, and a copy will be available on the Centessa website concurrent with the presentation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9510438-en) on August 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDL85NLVM:1","article_id":"2558649104","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2558649104","pubTimestamp":1754996525,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, has announced significant progress in its orexin receptor 2  agonist pipeline. The company reported that its ORX750 Phase 2a CRYSTAL-1 study, targeting narcolepsy type 1 , narcolepsy type 2 , and idiopathic hypersomnia , is on track with data expected to be released later this year. Additionally, Centessa has initiated a Phase 1 clinical trial of ORX142, focusing on acutely sleep-deprived healthy volunteers, with results anticipated in 2025. Furthermore, ORX489 is currently in IND-enabling studies for the treatment of neuropsychiatric disorders. An abstract detailing the ORX750 study has been accepted for a poster presentation at the World Sleep 2025 Congress, and a copy will be available on the Centessa website concurrent with the presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","CNTA":"Centessa Pharmaceuticals plc","BK4112":"金融交易所和数据","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","BK4539":"次新股","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4535":"淡马锡持仓"},"translate_title":"Centessa Pharmaceuticals启动ORX142针对睡眠不足志愿者的1期临床试验，预计2025年将获得关键数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNTA":0.9,"NDAQ":0.9},"content_text":"Centessa Pharmaceuticals Initiates Phase 1 Clinical Trial of ORX142 for Sleep-Deprived Volunteers, Expects Key Data in 2025\n    \n\nCentessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, has announced significant progress in its orexin receptor 2 (OX2R) agonist pipeline. The company reported that its ORX750 Phase 2a CRYSTAL-1 study, targeting narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia $(IH)$, is on track with data expected to be released later this year. Additionally, Centessa has initiated a Phase 1 clinical trial of ORX142, focusing on acutely sleep-deprived healthy volunteers, with results anticipated in 2025. Furthermore, ORX489 is currently in IND-enabling studies for the treatment of neuropsychiatric disorders. An abstract detailing the ORX750 study has been accepted for a poster presentation at the World Sleep 2025 Congress, and a copy will be available on the Centessa website concurrent with the presentation.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9510438-en) on August 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}